Nonprofit reacquires rights to TB drug after huge price hike

A huge overnight price increase for an important tuberculosis drug has been rescinded after the company that acquired the drug gave it back to its previous owner under pressure, it was announced Monday. Hasler said the foundation spent Monday reversing the price hike charged by Rodelis on roughly 30 orders of the 30-capsule blister packs.

Now, the Purdue University-affiliated organisation has brought the price back to $US1,050 for 30 capsules, according to the New York Times. Under the price Rodelis planned to charge, a full course of treatment would have cost more than $500,000 for cycloserine alone.

But it doesn’t look like the company that initially struck the high-drug-price nerve will follow in Rodelis’s footsteps. The drug combination was successful in eliminating the virus 99% of the time after patients with six strains, or genotypes, of the virus underwent 12 weeks of therapy.

Armstrong added that the price hike also caused an apparent shortage in the supply, and has affected her medical practice and various drug assistance programs.

And Rodelis’ recent business dealing – in which a pharmaceutical company purchases an old, neglected drug and turns it into a costly specialty medicine – has particularly caught consumers’ attention.

Clinton was referring to the actions of Turing Pharmaceuticals, which last month acquired Daraprim, a 62-year-old drug used to treat a serious parasitic infection, and raised its price to $750 per tablet, from $13.50.

Turing’s founder and chief executive, Martin Shkreli, has been vehemently defending his decision, arguing bigger pharma companies do similar things to fund further research into making the drug better. Judith Aberg, a spokesperson for the HIV Medicine Association, told USA Today that the classification of Daraprim and other specialty medicines leave even people with insurance struggling to pay for the drugs’ out-of-pocket costs. Democratic presidential candidates Hillary Clinton and Sen.